These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32298756)

  • 1. Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches.
    Kato T; Nakagawa H; Mikkaichi T; Miyano T; Matsumoto Y; Ando S
    Eur J Pharm Biopharm; 2020 Jun; 151():45-52. PubMed ID: 32298756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation.
    Zhang F; Zhou Y; Wu N; Jia R; Liu A; Liu B; Zhou Z; Hu H; Han Z; Ye X; Ding Y; He Q; Wang H
    Eur J Pharm Sci; 2021 Feb; 157():105618. PubMed ID: 33122011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic modeling. case example: Naproxen.
    Loisios-Konstantinidis I; Cristofoletti R; Fotaki N; Turner DB; Dressman J
    Eur J Pharm Sci; 2020 Feb; 143():105170. PubMed ID: 31783158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
    Willmann S; Thelen K; Lippert J
    J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development.
    Rebeka J; Jerneja O; Igor L; Boštjan P; Aleksander B; Simon Ž; Albin K
    AAPS PharmSciTech; 2019 Jan; 20(2):59. PubMed ID: 30623248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of In Silico Pharmacokinetic Modeling Approaches Into In Vitro Dissolution Profiles to Predict Bioavailability of a Poorly Soluble Compound.
    Kato T; Watanabe T; Nakamura K; Ando S
    J Pharm Sci; 2019 Nov; 108(11):3723-3728. PubMed ID: 31278915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption.
    Laisney M; Heimbach T; Mueller-Zsigmondy M; Blumenstein L; Costa R; Ji Y
    J Pharm Sci; 2022 Jan; 111(1):274-284. PubMed ID: 34678270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of in vitro biorelevant dissolution and in silico PBPK model of carvedilol to predict bioequivalence of oral drug products.
    Ibarra M; Valiante C; Sopeña P; Schiavo A; Lorier M; Vázquez M; Fagiolino P
    Eur J Pharm Sci; 2018 Jun; 118():176-182. PubMed ID: 29605455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation.
    Ellison CA
    Regul Toxicol Pharmacol; 2018 Nov; 99():61-77. PubMed ID: 30201539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro-In vivo Relationship and Bioequivalence Prediction for Modified-Release Capsules Based on a PBPK Absorption Model.
    Jereb R; Opara J; Legen I; Petek B; Grabnar-Peklar D
    AAPS PharmSciTech; 2019 Dec; 21(1):18. PubMed ID: 31820131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development, validation and application of physiologically based biopharmaceutics model to justify the change in dissolution specifications for DRL ABC extended release tablets.
    Jaiswal S; Ahmed T; Kollipara S; Bhargava M; Chachad S
    Drug Dev Ind Pharm; 2021 May; 47(5):778-789. PubMed ID: 34082622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current status and future opportunities for incorporation of dissolution data in PBPK modeling for pharmaceutical development and regulatory applications: OrBiTo consortium commentary.
    Jamei M; Abrahamsson B; Brown J; Bevernage J; Bolger MB; Heimbach T; Karlsson E; Kotzagiorgis E; Lindahl A; McAllister M; Mullin JM; Pepin X; Tistaert C; Turner DB; Kesisoglou F
    Eur J Pharm Biopharm; 2020 Oct; 155():55-68. PubMed ID: 32781025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Justification of Biowaiver and Dissolution Rate Specifications for Piroxicam Immediate Release Products Based on Physiologically Based Pharmacokinetic Modeling: An In-Depth Analysis.
    Li X; Yang Y; Zhang Y; Wu C; Jiang Q; Wang W; Li H; Li J; Luo C; Wu W; Wang Y; Zhang T
    Mol Pharm; 2019 Sep; 16(9):3780-3790. PubMed ID: 31398041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Impact of Drug Crystallinity in Amorphous Tacrolimus Capsules on Pharmacokinetics and Bioequivalence Using Discriminatory In Vitro Dissolution Testing and Physiologically Based Pharmacokinetic Modeling and Simulation.
    Purohit HS; Trasi NS; Sun DD; Chow ECY; Wen H; Zhang X; Gao Y; Taylor LS
    J Pharm Sci; 2018 May; 107(5):1330-1341. PubMed ID: 29289674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring clinically relevant dissolution specifications for oral solid dosage forms of weak acid drugs using an in silico modeling and simulation approach.
    Kambayashi A; Yomota C
    Eur J Pharm Sci; 2021 Apr; 159():105728. PubMed ID: 33484814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model.
    Tang C; Ou-Yang CX; Chen WJ; Zou C; Huang J; Cui C; Yang S; Guo C; Yang XY; Lin Y; Pei Q; Yang GP
    Eur J Pharm Sci; 2022 Jan; 168():106055. PubMed ID: 34742834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure.
    Mukherjee D; Chiney MS; Shao X; Ju TR; Shebley M; Marroum P
    Biopharm Drug Dispos; 2022 Jun; 43(3):98-107. PubMed ID: 35405765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In Vitro-In Vivo Correlation Using In Silico Modeling of Physiological Properties, Metabolites, and Intestinal Metabolism.
    Choi SM; Kang CY; Lee BJ; Park JB
    Curr Drug Metab; 2017; 18(11):973-982. PubMed ID: 29086683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using a Physiologically Based Pharmacokinetic Absorption Model to Establish Dissolution Bioequivalence Safe Space for Oseltamivir in Adult and Pediatric Populations.
    Miao L; Mousa YM; Zhao L; Raines K; Seo P; Wu F
    AAPS J; 2020 Aug; 22(5):107. PubMed ID: 32779046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of PBPK/PD to establish clinically relevant dissolution specifications for zolpidem immediate release tablets.
    Paraiso RLM; Rose RH; Fotaki N; McAllister M; Dressman JB
    Eur J Pharm Sci; 2020 Dec; 155():105534. PubMed ID: 32871212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.